In addition, preclinical and human studies suggest that kappa opioid receptor (KOR) antagonists may have therapeutic utility in the treatment of mood disorders and drug addiction2, 3, however, selective KOR antagonists have unexplained pharmacological properties, including a long duration of action, that limit their utility2, 4–6. The gene discussed is OPRK1; the disease is mood disorder.